Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Dr Reddy's...

    Dr Reddy's Laboratories in process to seek permission for launch of 70 products in China

    Farhat NasimWritten by Farhat Nasim Published On 2019-06-03T11:00:21+05:30  |  Updated On 16 Aug 2021 3:17 PM IST

    Dr Reddy's Chief Operations Officer, Erez Israeli in a recent earnings call said the drug-maker is in the process of seeking necessary approvals from Chinese authorities for selling drugs including in oncology area there and is upgrading professional teams for the growth.


    New Delhi: With incipient regulatory changes in China on Indian drug imports, Dr Reddy's Laboratories has identified about 70 products for the country to be launched in a few years and is also planning to build a new plant very close to the existing one.


    Dr Reddy's Chief Operations Officer, Erez Israeli in a recent earnings call said the drug-maker is in the process of seeking necessary approvals from Chinese authorities for selling drugs including in oncology area there and is upgrading professional teams for the growth.


    "China is an important space for us and we see a major opportunity in China. As China opened, especially with the changes of regulations to the kind of products in terms of quality and cost-effective that we can build to China.


    "We identified 70 products, 7-0 products that -- from our US portfolio that reached those requirements, and we hopefully and potentially can obtain in the next coming years, new ways and strategies for them," he said replying to a query.







    DRL has a subsidiary Dr Reddy's (WUXI) Pharmaceutical Co. Limited and joint venture Kunshan Rotam Reddy Pharmaceuticals Company Limited is engaged in the manufacturing and marketing of formulations in China.

    Also Read: Dr Reddy's Laboratories signs MOU for employee skill development

    The company's interest in Reddy Kunshan was 51.3 per cent as of March 31, 2018.

    "We are upgrading our team in China and we are also going to build a new plant very close to the current plant that we have. So overall, very exciting opportunities," Israeli further said.

    When contacted, Dr Reddy's spokesperson said the company generated approximately USD 130 million during the last fiscal and it is all through product sales.

    "It(China sales)is expected to be growing healthy. We do not give number guidance. Approx. USD 130 mn (million)in FY 2019 including the revenue in our joint venture. It is all product sale, no services. (We plan to launch)50 to 70 over a period of next few years," the official told PTI in an email reply.

    A top Commerce Department official recently said India pressed China to import more Indian goods, especially pharmaceutical and IT products.

    Recently, India has identified and shared with China a list of 380 products, including horticulture, textiles, chemicals and pharmaceutical products, as their shipments hold huge export potential.

    "The(product)filing is happening as we speak, and so in the next three to four years, some of the products are ready to be filed because all the relevant Research and Development and regulatory process were done," he said.

    "And some will require a bio-study and some will require production by the relevant oncology plant in China, and those products have been put forth," he explained.



    chinaChina drug marketChinese approvalDr Reddy'sDr Reddy's LaboratoriesDr Reddy's LabsDRLdrugsindian drug marketIndian goodsKunshan Rotam Reddy Pharmamedicinesoncologypharmapharma news indiaReddy PharmaUS portfolioWUXIWUXI pharma
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok